文献速递浆细胞疾病造血干细胞移植与细胞治疗

难治复发性多发性骨髓瘤患者BCMA-CAR-T细胞治疗期间血清脂质水平与营养状态的变化及意义:基于LEGEND-2的回顾性研究

[Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2023-01-01

基于LEGEND-2研究,回顾性分析57例难治复发性多发性骨髓瘤患者接受BCMA-CAR-T细胞治疗前后血清脂质水平与CONUT评分的变化;输注后8~14天血脂与白蛋白降至最低、CONUT评分达最高,治疗后血脂与营养状态显著改善;高CONUT评分组中位总生存期较低CONUT评分组缩短(P=0.046)。

要点

  • CAR-T输注后8~14天TC、HDL、LDL、Apo A1、ALB降至最低,CONUT评分达最高,TG与Apo B较基线升高。
  • 输注后TC、HDL、Apo A1水平与CRS分级呈显著负相关(r=-0.548、-0.444、-0.589)。
  • 高CONUT评分组中位OS较低CONUT评分组缩短(P=0.046),CONUT评分与PFS无关。

核心结论

  • CAR-T细胞治疗期间患者血脂水平降低及营养状态不良加剧,可能与CRS有关;治疗后血脂水平及营养状态显著改善。
  • CONUT评分是影响CAR-T细胞治疗患者总生存期的因素,作者认为需要对接受CAR-T细胞治疗患者的营养状态进行针对性筛查和干预。

研究设计与样本

  • 基于LEGEND-2研究的回顾性研究,纳入2016年3月至2018年2月在西安交通大学第二附属医院行BCMA-CAR-T细胞治疗的57例R/R MM患者。
  • 比较CAR-T输注前后不同时间点血清脂质水平、CONUT评分等临床指标。
  • 通过ROC曲线确定最佳截断值,将患者分为高CONUT评分组(>6.5分,营养状况不良组)和低CONUT评分组(≤6.5分,营养状况良好组)。
  • 采用Kaplan-Meier生存分析比较两组PFS期及OS期。

主要发现

  • CAR-T输注前,除TG外患者血清脂质水平平均低于正常。
  • CAR-T输注后8~14 d内,ALB、TC、HDL、LDL和Apo A1水平降至最低,CONUT评分达到最大值,TG和Apo B水平较输注前升高。
  • CAR-T细胞治疗后,患者血清脂质水平显著升高,营养状态显著改善。
  • Spearman相关分析示输注后TC、HDL、Apo A1水平与CRS分级呈显著负相关(r=-0.548,P=0.003;r=-0.444,P=0.020;r=-0.589,P=0.001)。
  • 生存分析示CONUT评分与PFS无关,高CONUT评分组中位OS较低CONUT评分组缩短(P=0.046)。

关键数值与推荐

  • CONUT评分截断值为6.5分:>6.5分为高CONUT评分组(营养状况不良组),≤6.5分为低CONUT评分组(营养状况良好组)。
  • 输注后TC与CRS分级相关:r=-0.548,P=0.003。
  • 输注后HDL与CRS分级相关:r=-0.444,P=0.020。
  • 输注后Apo A1与CRS分级相关:r=-0.589,P=0.001。
  • 高CONUT评分组与低CONUT评分组中位OS比较:P=0.046。

临床怎么用

  • 作者结论认为,需要对接受CAR-T细胞治疗患者的营养状态进行针对性筛查和干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the dynamic changes in serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma (R/R MM) based on LEGEND-2. Methods: The data of patients with R/R MM who underwent BCMA-CAR-T therapy at our hospital between March 30, 2016, and February 6, 2018, were retrospectively collected. Serum lipid levels, controlled nutritional status (CONUT) score, and other clinical indicators at different time points before and after CAR-T-cell infusion were compared and analyzed. The best cut-off value was determined by using the receiver operator characteristic (ROC) curve. The patients were divided into high-CONUT score (>6.5 points, malnutrition group) and low-CONUT score groups (≤6.5 points, good nutrition group), comparing the progression-free survival (PFS) and total survival (OS) of the two groups using Kaplan-Meier survival analysis. Results: Before the infusion of CAR-T-cells, excluding triglycerides (TG), patients' serum lipid levels were lower than normal on average. At 8-14 d after CAR-T-cell infusion, serum albumin (ALB), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and apolipoprotein A1 (Apo A1) levels dropped to the minimum, whereas CONUT scores reached the maximum. In addition to TG, apolipoprotein B (Apo B) levels increased compared with baseline. After CAR-T-cell therapy, the patients' serum lipid levels significantly increased with well-improved nutritional status. Spearman's related analysis showed that TC, HDL, and ApoA1 levels after CAR-T-cell injection were significantly negatively correlated with the grade of cytokine-release syndrome (CRS) (r=-0.548, P=0.003; r=-0.444, P=0.020; r=-0.589, P=0.001). Furthermore, survival analysis indicated that the CONUT score was unrelated to PFS, and the median OS of patients with R/R MM in the high-CONUT score group was shorter than that in the low-CONUT score group (P=0.046) . Conclusions: During CAR-T-cell therapy, hypolipidemia and poor nutritional status were aggravated, which is possibly related to CRS. The patients' serum lipid levels and nutritional status were significantly improved after CAR-T-cell treatment. The CONUT score affected the median OS in patients treated with CAR-T-cells. Therefore, specific screening and intervention for nutritional status in patients receiving CAR-T-cell therapy are required. 目的: 基于LEGEND-2研究探讨BCMA-CAR-T细胞治疗难治复发性多发性骨髓瘤(R/R MM)期间血清脂质水平和营养状态的变化。 方法: 以2016年3月至2018年2月在西安交通大学第二附属医院行BCMA-CAR-T细胞治疗的57例R/R MM患者为研究对象,回顾性分析CAR-T治疗前后不同时间点的血清脂质水平、控制营养状况(CONUT)评分等临床指标的变化。通过ROC曲线确定最佳截断值,将患者分为高CONUT评分组(>6.5分,营养状况不良组)和低CONUT评分组(≤6.5分,营养状况良好组),通过Kaplan-Meier生存分析对比两组的无进展生存(PFS)期及总生存(OS)期。 结果: 输注CAR-T细胞前,患者血清脂质水平除甘油三酯(TG)外均低于正常水平。在CAR-T细胞输注后8~14 d内,血清白蛋白(ALB)、总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)和载脂蛋白A1(Apo A1)水平降至最低,CONUT评分达到最大值,而TG、载脂蛋白B(Apo B)水平较输注前升高。CAR-T细胞治疗后,患者的血清脂质水平显著升高,同时营养状态显著改善。Spearman相关分析显示,CAR-T细胞输注后TC、HDL和Apo A1的水平与细胞因子释放综合征(CRS)分级呈显著负相关(r=-0.548,P=0.003;r=-0.444,P=0.020;r=-0.589,P=0.001)。生存分析提示,输注前的CONUT评分与PFS无关,高CONUT评分组MM患者较低CONUT评分组患者的中位OS期缩短(P=0.046)。 结论: CAR-T细胞治疗期间患者的血脂水平降低及营养状态不良加剧,这可能与CRS有关;CAR-T细胞治疗后患者血脂水平及营养状态会显著改善。营养状况CONUT评分是影响CAR-T细胞治疗患者OS的因素。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Xu XZ, Liu R, Zhao WH, et al. [Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 38049336. doi:10.3760/cma.j.issn.0253-2727.2023.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。